WHAT WE DO
Built in the lab. Validated in the clinic. Exited to global pharma.
Tzientzia is the operating vehicle of Diogo R. Anjos — co-founder and CEO of Lymphact, the first Portuguese Biotech company to achieve a successful exit. Lymphact was acquired by Takeda Pharmaceuticals in 2018 (Achieving all rollout milestones by 2021).
I have built, regulated, funded, and exited a cell therapy company. That is the only experience worth passing on.”
Diogo R. Anjos
CEO
Tzientzia services
How we work
Service blocks
Board Advisory
Board-level engagement with cell and gene therapy companies at Series A and beyond — scientific strategy, regulatory positioning, investor narrative, and governance. Equity-based. A small number of concurrent seats.
Operating Partnership
Deep, hands-on operating engagement for fund portfolios that need a DeepTech Biotech operator alongside management. Day-rate plus equity. One company at a time.
Fund Collaboration
Operating and venture partner arrangements with life sciences funds — portfolio diligence, founder assessment, and post-investment operational support, preferably in cell and gene therapy.
Services
The track record
>40 Patents
granted
>20x
Exit
+1000
pitches
Who we are and what we do
Tzientzia is a spinoff of the first Portuguese successful exit startup Lymphact.
In 2018, Lymphact was acquired by Takeda Pharmaceuticals.
Tzientzia now deploys that operating experience at board level — working with a select number of deep tech companies in healthcare and beyond, and the funds backing them.
Board-level strategy support – Board-level advisory and operating partnerships — for funded advanced therapeutics companies and the funds backing them. A small number of engagements at any given time, structured around advisory equity or retainer.
Tzientzia does not offer general consulting. If you have been pointed here by someone who knows our work, reach out.